Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175, is a Type-1 Board within the Division of Insurance that will have the authority to review prescription drug costs and evaluate their impact on Coloradans. The Board may then recommend ways to address those costs and may set an upper payment limit for certain drugs. The Board has appointed a multi-stakeholder Advisory Council to provide input to the Board to ensure its work is informed by a variety of stakeholders.
To receive PDAB and PDAAC updates directly in your inbox, click the button below. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
Prescription Drug Affordability Board (PDAB)
PDAB Meetings & Meeting Materials
The Prescription Drug Affordability Board, in accordance with statute, will hold regular meetings every six weeks. All meetings are open to the public except portions of the meeting in which confidential information may be discussed. Board meetings will now be held on the Zoom platform.
Next PDAB meeting: Friday, February 17 from 10 am - 2 pm MT
The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:
- Collect and evaluate data to identify drugs that may be subject to an affordability review;
- Perform affordability reviews if certain statutory triggers occur;
- Determine whether a prescription drug is unaffordable for Colorado consumers;
- If a drug is found to be unaffordable, the Board may set an upper payment limit; and
- Make policy recommendations to the General Assembly.
- Board Members
The Governor appointed the following Prescription Drug Affordability Board Members on September 27, 2021:
- Sami Diab, MD of Greenwood Village, Colorado
- Amarylis “Amy” Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger of Holyoke, Colorado
- Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado and to serve as Board Chair
- James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
Prescription Drug Affordability Advisory Council (PDAAC)
PDAAC Meetings & Meeting Materials
The Prescription Drug Affordability Advisory Council (PDAAC), in accordance with statute, will hold meetings quarterly. Advisory Council meetings will now be held on the Zoom platform. There will be opportunity for public comment at PDAAC meetings.
Next PDAAC meeting: Thursday, February 23 from 9 - 11 am MT
The Board has appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input to the Board on prescription drug affordability.
All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise.
To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.
- Council Members
- Kim Bimestefer Executive Director of HCPF
- Gail deVore representing health care consumers
- Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
- Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair
- Maria Fenwick representing a labor union
- Nathan Wilkes representing employers
- Chad Friday representing carriers
- Marc Reece representing pharmacy benefit managers
- Thomas Tobin, MD, MBA representing health care professionals with prescribing authority
- R. Brett McQueen, PhD representing an organization that researches prescription drugs
- Katelin Lucariello MPH representing manufacturers of brand name drugs
- Neal Miller representing manufacturers of generic drugs
- Andrew Gonzales, PharmD representing pharmacists
- Jason Atlas, RPh, MBA representing wholesalers
- Learning Series & Resources
Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.
Learning Series 1: Data Deep Dive
Learning Series 2: Patient Perspectives
Learning Series 3: Pharmaceutical Supply Chain Panel
Learning Series 4: Comparative Effectiveness & Affordability
Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States
- Contact Information & Accessibility
Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to email@example.com.
The Prescription Drug Affordability Program is committed to providing equal access to our meetings for all participants. If you would like to request an accommodation to attend a Board or Advisory Council meeting, please contact us at firstname.lastname@example.org with your request by the close of business at least one week in advance of a meeting.
- Conflict of Interest Information
Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.